Vaccitech Newsroom

Contract includes funding to conduct one of the largest influenza A challenge studies Vaccitech announced today that it has been awarded a contract valued at $8.5 million from the Biomedical Advanced Research and Development Authority (BARDA), a component of the U.S....

To assist with the coordination and oversight of cross-functional activities to support the Vaccitech portfolio of research and development programmes. All activities carried out within allocated time, and agreed costs and in accordance with quality requirements,...

Vaccitech will progress existing vaccine programs and the collaboration will combine Vaccitech’s know-how with GeneMatrix’s clinical network. Oxford, UK and Seoul, South Korea Vaccitech, a clinical stage developer of a universal flu vaccine and other vaccine-related...

The role of the senior scientist will be to design, conduct, optimize and evaluate new processes in viral vector production. The senior scientist will also work to improve existing process design to improve efficiency and quality. They will monitor the field for new...

Vaccitech Ltd is seeking a molecular biologist to join a team focused on viral vectored vaccines research and development. The successful candidate will play a critical role in the development of new approaches to generate viral vaccine vectors, including (but not...

Vaccitech has taken the decision not to proceed with season 2 of the current FLU007 (Invictus) study due to the changes recommended by the UK Government which directed the NHS to use FLUAD (adjuvanted TIV) vaccine in the 65 year old and over population in the 2018/19...

CEPI Awards Contract Worth Up To USD$19 million to Oxford University and Janssen Vaccines to Develop MERS, Lassa, and Nipah Vaccines   Posted on http://cepi.net/node/425 27th September 2018 by Mario Christodoulou   OSLO (Norway), Oxford (UK) CEPI (the...

Vaccitech will combine Oxford University vaccine know-how with the manufacturing expertise of China’s CanSino Biologics in collaboration focused on herpes zoster. Vaccitech Limited, a UK-based company developing products to treat and prevent multiple infectious...

View/Download ASCO 2018 Poster

Vaccitech Limited, a UK company developing products to treat and prevent multiple infectious diseases and cancer, today announced the presentation of Phase 1 prostate cancer vaccine data at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. In...